Parkinson's Disease can indeed cause sleepiness, which is a common non-motor symptom experienced by many individuals with the condition. This sleepiness can manifest as excessive daytime sleepiness (EDS), where individuals feel an overwhelming need to sleep during the day.
If sleepiness significantly impacts daily life or safety, such as increasing the risk of falls or affecting the ability to drive, it is important to seek medical advice. A healthcare provider can help determine the cause and suggest appropriate interventions to manage this symptom effectively.
Many people with Parkinson's Disease experience sleepiness and fatigue, which are common non-motor symptoms. Here's a summary of patient discussions on this topic.
Overall, while sleepiness is a common issue for those with Parkinson's, there are various strategies and adjustments that can help manage this symptom. It's important for individuals to work closely with their healthcare providers to find the best approach for their specific situation.
Patient View
Any ideas how to manage tiredness and brain fog apart from taking naps/resting?
October 2024 • Turnto Crowd Question
Patient View
Anyone get very tired/fatigued on Selegeline?
September 2024 • Turnto Crowd Question
Research has shown that Parkinson's disease can indeed cause sleepiness, particularly excessive daytime sleepiness (EDS), which is a common non-motor symptom affecting many individuals with the condition. This symptom can significantly impact the quality of life and daily functioning of those affected by Parkinson's disease.
Excessive daytime sleepiness in Parkinson's disease is a well-researched topic, with numerous studies exploring its prevalence, underlying mechanisms, and potential treatments. The research community has shown a strong interest in understanding the multifactorial nature of EDS, which involves both disease-related and treatment-related factors. There is a consensus that EDS is a significant issue in Parkinson's disease, but opinions vary on the best approaches to manage it.
Prevalence and Impact
Underlying Mechanisms
Management Strategies
Independent Symptom
Treatment Efficacy
Predictors and Risk Factors
Understanding the complexities of excessive daytime sleepiness in Parkinson's disease is crucial for developing effective management strategies and improving the quality of life for those affected. Continued research is needed to address the unknowns and refine treatment approaches.
Research
This article investigates excessive daytime sleepiness (EDS) and unintended sleep episodes in Parkinson's disease (PD) patients, exploring the underlying causes and management strategies. It highlights the role of brainstem nuclei and communication pathways in sleep disorders, noting that EDS affects up to 50% of PD patients and is a persistent feature with multifactorial pathophysiology.
Key findings include the identification of EDS as a marker of preclinical and premotor PD, with both age and disease-related disturbances contributing to hypersomnia. Dopamine agonists are also implicated in EDS. Effective management of these sleep disturbances can significantly improve the quality of life for PD patients.
For those living with or caring for someone with PD, understanding the multifactorial nature of EDS and its management is crucial for improving daily functioning and quality of life.
The paper is reliable, published in the Oman Medical Journal, and provides a comprehensive overview of EDS in PD, supported by recent research findings.
April 2015 • Oman medical journal
Research
This review focuses on excessive daytime sleepiness (EDS) in Parkinson's disease (PD), examining its prevalence, underlying mechanisms, and the impact of antiparkinsonian drugs. It highlights the degeneration of wake-promoting nuclei as a key factor in EDS pathogenesis and discusses the effects of altered neurotransmitter systems.
Key findings include the high morbidity and poor quality of life associated with EDS in PD, as well as the role of antiparkinsonian drugs in exacerbating EDS. The review suggests that understanding these mechanisms could lead to novel interventions for EDS in PD patients.
For those affected by PD, this research underscores the importance of addressing EDS to improve quality of life and reduce accident risks.
The paper is published in the reputable journal Nature and Science of Sleep, providing a comprehensive review of current literature and offering insights into potential therapeutic targets for EDS in PD.
September 2022 • Nature and science of sleep
Excessive sleepiness is a common issue for individuals with Parkinson's, often manifesting as excessive daytime sleepiness (EDS). This can be attributed to several factors, including the disease's impact on sleep regulation and the side effects of medications used to manage Parkinson's symptoms.
Understanding and managing sleepiness in Parkinson's is essential for maintaining quality of life and safety, especially when it comes to activities like driving. If sleepiness becomes a significant issue, it's important to consult with a healthcare provider to explore potential solutions.
Video
Dr. Gary Leo discusses how medications used to treat Parkinson's, such as dopamine agonists, can cause daytime sleepiness. He emphasizes the importance of adjusting medications to reduce sleepiness and highlights the role of lack of daytime activity in contributing to sleepiness.
July 2024 • Davis Phinney Foundation for Parkinson's
Video
Dr. Ruchir P. Patel explains that excessive daytime sleepiness affects about 21% of Parkinson's patients. It can be caused by the disease's neurodegenerative process, sleep disorders, and medications. Treating underlying sleep disorders and adjusting medications are crucial steps.
December 2021 • Movement Disorders Foundation of Arizona
Was this helpful?
This is not healthcare advice or a recommendation. This tool is in beta and currently experimental. It is designed to help you find the most recent and helpful sources, from different voices, for you to take to consider with your healthcare team.
We appreciate any feedback as we aim to help speed up breakthroughs for all conditions.
© 2026 Turnto